Lodestar Private Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$969K Sell
4,456
-236
-5% -$52.4K 0.1% 106
2025
Q4
$1.07M Sell
4,692
-297
-6% -$67.7K 0.11% 97
2025
Q3
$1.16M Sell
4,989
-117
-2% -$23.8K 0.12% 93
2025
Q2
$948K Sell
5,106
-265
-5% -$49.3K 0.11% 101
2025
Q1
$1.13M Sell
5,371
-193
-3% -$37.5K 0.14% 94
2024
Q4
$989K Sell
5,564
-25
-0.4% -$4.6K 0.12% 100
2024
Q3
$1.1M Buy
5,589
+6
+0.1% +$1.12K 0.14% 92
2024
Q2
$958K Sell
5,583
-194
-3% -$32.1K 0.13% 99
2024
Q1
$1.05M Sell
5,777
-107
-2% -$18.4K 0.15% 95
2023
Q4
$912K Sell
5,884
-55
-0.9% -$8.02K 0.14% 95
2023
Q3
$885K Sell
5,939
-187
-3% -$27.5K 0.15% 94
2023
Q2
$825K Buy
6,126
+2,667
+77% +$391K 0.14% 98
2023
Q1
$551K Buy
3,459
+92
+3% +$14.1K 0.1% 115
2022
Q4
$544K Buy
+3,367
New +$516K 0.1% 117

Other funds holding ABBV

Lodestar Private Asset Management's ABBV Position: Q1 2026 in Review

Lodestar Private Asset Management reduced its AbbVie (ABBV) stake by 5% in Q1 2026, selling an estimated $52.4K and leaving 4,456 shares worth $969K. The position accounts for 0.1% of the portfolio, ranked #106.

Lodestar Private Asset Management first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.16M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Lodestar Private Asset Management held 4,456 shares of AbbVie worth $969K as of Q1 2026.
  • Lodestar Private Asset Management sold 236 AbbVie shares in Q1 2026, an estimated $52.4K.
  • AbbVie made up 0.1% of Lodestar Private Asset Management's portfolio in Q1 2026, its #106 holding.
  • Lodestar Private Asset Management first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • Lodestar Private Asset Management's AbbVie position peaked at $1.16M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Lodestar Private Asset Management's 13F filing for Q1 2026, filed 27 Apr 2026.